Skip Navigation
Find a Doctor
 
 
 
 

 

Search for
other physicians or researchers.

Find a Doctor
Photo of Dr. David Peter Cosgrove, MBBCh

David Peter Cosgrove, MBBCh

Assistant Professor of Oncology
Male
Appointment Phone

410-955-8964

Primary Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Assistant Professor of Oncology

Centers & Institutes

  • Sidney Kimmel Comprehensive Cancer Center
  • Skip Viragh Center for Pancreas Cancer

Expertise

Anal Cancer, Bile Duct Cancer, Cancer of Unknown Primary, Carcinoid Syndrome, Carcinoid Tumors, Cholangiocarcinoma, Clinical Trials, Colon Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Gastrointestinal Cancers, Gastrointestinal Tumors, Hepatocellular Cancer, Liver Cancer, Medical Oncology, Neuroendocrine Tumors, Pancreatic Cancer, Rectal Cancer, Small Bowel Cancer, Stomach Cancer

Research Interests

Hepatocellular carcinoma; Biliary tract malignancies, as well as carcinoma of unknown primary site; Gastrointestinal malignancies

Biography

Dr. Cosgrove aims to identify molecular biomarkers in cancer cells that can differentiate them from normal cells. These differences at the genetic and molecular level should allow us to develop drugs that will target only the cancer cells, and have minimal side effects on the patients normal cells. He is working closely with the gastrointestinal malignancies group to bring new drugs and combinations into clinical practice. The ultimate goal is to identify the best drug, or combination of drugs, for individual patients based upon their tumors genetic makeup. The same approach should also allow us to identify drugs that will not be effective against particular tumors, so ineffective therapy can be avoided.

Languages

  • English
  • German

Clinical Trial Keywords

  • Phase I, gastrointestinal malignancies,hepatocellular carcinoma and biliary tract malignancies,carcinoma of unknown primary site.

Additional Resources

Additional Resources +
  • Education +

    Training

    • Faculty of Medicine National University of Ireland ( DUBLIN 2) (2000)

    Residencies

    • The Johns Hopkins Hospital/Internal Medicine ( Baltimore MD ) (2006)
    • James Connolly Memorial Hospital/Internal Medicine ( Dublin 15) (2002)

    Fellowships

    • The Johns Hopkins Hospital/Medical Oncology ( Baltimore MD ) (2009)

    Certifications

    • Medical Oncology, American Board of Internal Medicine (2008)
    • Internal Medicine, American Board of Internal Medicine (2007)
  • Research & Publications +

    Selected Publications

    Research Summary

    Dr. Cosgroves research is focused on molecular changes in tumor cells, specifically within proliferation pathways such as MAPK and PISK/AKT. He is developing agents to target these pathways, and biomarkers to identify patients most likely to benefit from such agents.

    Peer Reviewed Articles

    1. Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, Vitolo MI, Bachman KE, Park BH. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A. 2009;106(8):2835-40. PMCID: 2636736.

    2. Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, Garay JP, Mohseni M, Wang GM, Higgins MJ, Gorkin D, Reis M, Vogelstein B, Polyak K, Cowherd M, Buckhaults PJ, Park BH. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene. 2010;29(16):2337-45. PMCID: 3042798.

    3. Demirjian A, Peng P, Geschwind JF, Cosgrove D, Schutz J, Kamel IR, Pawlik TM. Infiltrating hepatocellular carcinoma: seeing the tree through the forest. J Gastrointest Surg. 2011;15(11):2089-97. PMCID: Not supported through NIH funds.

    4. Higgins MJ, Beaver JA, Wong HY, Gustin JP, Lauring JD, Garay JP, Konishi H, Mohseni M, Wang GM, Cidado J, Jelovac D, Cosgrove DP, Tamaki A, Abukhdeir AM, Park BH. PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells. Cancer Biol Ther. 2011;11(3):358-67. PMCID: 3047087.

    5. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A. 2011;108(43):17773-8. PMCID: 3203756.

    6. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011;29(30):3960-7. PMCID: Not supported through NIH funds.

    7. De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D, Le DT, Chung K, Diaz LA, Jr. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2012;69(2):415-24. PMCID: 3265723.



    Book Chapters

    1. Cosgrove D, Mouden M, Wise R. Chronic Obstructive Pulmonary Disease. In: Nilsson P, editor. Osler Handbook of Clinical Medicine, 2nd Edition. Philadelphia: Elsevier; 2006.

    2. Cosgrove D, Donehower R. Adenocarcinoma of Unknown Primary [database on the Internet]. BMJ Group 2010 [cited 07/2010].

    3. Cosgrove D, Park BH, Vogelstein B. Tumor Suppressor Genes. In: Waun Ki Hong, editor. Holland-Frei Cancer Medicine. Shelton: BC Decker/ American Association for Cancer Research; 2010. p. 86-102.


    Reviews
    1. Gustin JP, Cosgrove DP, Park BH. The PIK3CA gene as a mutated target for cancer therapy. Curr Cancer Drug Targets. 2008;8(8):733-40. PMCID: 2831175.

    2. Pawlik TM, Cosgrove D. The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? J Gastrointest Surg. 2011;15(3):410-5.

    3. Kneuertz PJ, Cosgrove DP, Cameron AM, Kamel IR, Geschwind JF, Herman JM, Pawlik TM. Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation. J Gastrointest Surg. 2012;16(4):874-81. PMCID: Not funded through NIH support.


  • Academic Affiliations & Courses +
  • Activities & Honors +
  • Videos & Media +
  • Upcoming Events +
  • Contact & Locations +

    Locations

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Appointment Phone: 410-955-8964
    Location Map

    Department/Division

    • Oncology

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer